Drawing for VECTURA V

USPTO serial 79204968

VECTURA V

Reviewed by CopyMark Law Group

Reg. 5398606Status 709
Filing date
Status date
Registration date
Feb 13, 2018
Examiner
MARTIN, CHRISTINE C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VECTURA V?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Molly B. Markley

Molly B. Markley Young Basile Hanlon & MacFarlane P.C.3001 West Big Beaver RoadSuite 624Troy, MI 48084-3107

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and biological preparations for medical purposes, namely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposes, namely the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposes, namely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposes, namely, powders for asthma inhalers; pharmaceutical and biological preparations for medical purposes, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genitourinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purpose, namely, medicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposes, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purpose, namely medicaments for the treatment of erectile dysfunction, medicaments for the treatment of chronic obstructive pulmonary disease, medicaments for the treatment of premature ejaculation, medicaments for the treatment of cystic fibrosis, medicaments for the treatment of female sexual dysfunction, medicaments for the treatment of migraines, medicaments for the treatment of asthmaSECTION 71 - CANCELLED—
010Medical apparatus and instruments, namely drug delivery devices, namely drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goodsSECTION 71 - CANCELLED—
042Scientific research, development, design, analysis, testing and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testingSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 15, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 27, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 5, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Aug 16, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 16, 2025INPCINVALIDATION PROCESSED—
Apr 30, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 30, 2024C71TCANCELLED SECTION 71—
Dec 22, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 13, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 8, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 13, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 23, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 23, 2018FIMPFINAL DISPOSITION PROCESSED—
May 13, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 13, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 8, 2017GPNXNOTIFICATION PROCESSED BY IB—
Nov 28, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 28, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 22, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 22, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Nov 8, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 20, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 11, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 11, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 11, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 13, 2017RFNTREFUSAL PROCESSED BY IB—
Apr 25, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 24, 2017RFRRREFUSAL PROCESSED BY MPU—
Apr 20, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 19, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 14, 2017DOCKASSIGNED TO EXAMINER—
Apr 14, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 13, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance